Abstract:PurposeTo compare gadobutrol and gadopentetate dimeglumine (Gd-DTPA) contrast-enhanced magnetic resonance imaging (MRI) at 3T for visualizing brain metastases. Materials and MethodsThe present randomized study included 60 consecutive patients with known or suspected brain metastases from systemic malignancies. Two enhanced cerebral MR scans were performed in each patient within an interval of 2-5 days using different contrast agents (gadobutrol or Gd-DTPA) at 3T. The dose of the contrast agents (0.1 mmol/kg Gd) was also identical. The axial T-1 FLAIR images at 3, 7, and 10 minutes after the injection of the contrast agent were obtained for evaluation. Two experienced radiologists performed subjective evaluation of the image quality, made the choice of the optimal images, and performed an objective evaluation including: signal-to-noise ratio (SNR) of the brain metastases, contrast-to-noise ratio (CNR), contrast enhancement (CE), contrast-to-brain ratio (CBR), and contrast enhancement ratio (CER) of the brain metastases. ResultsSubjective evaluation showed that at 3, 7, and 10 minutes gadobutrol elicited higher scores (margin score: 3.560.74 vs. 3.330.93, 3.680.57 vs. 3.45 +/- 0.81, 3.58 +/- 0.71 vs. 3.43 +/- 0.76; interior score: 2.83 +/- 0.42 vs. 2.63 +/- 0.61, 2.86 +/- 0.38 vs. 2.73 +/- 0.52, 2.80 +/- 0.42 vs. 2.69 +/- 0.53; and overall score: 4.42 +/- 0.98 vs. 4.09 +/- 1.19, 4.57 +/- 0.75 vs. 4.26 +/- 1.05, 4.48 +/- 0.83 vs. 4.21 +/- 1.03, respectively) in displaying the details and overall lesions than Gd-DTPA (repeated measures analysis of variance [ANOVA], margin score: P=0.001, < 0.0001, 0.006; interior score: P < 0.0001, 0.004, 0.009; and overall score: P=0.001, < 0.0001, < 0.0001, respectively). Subjective optimal image evaluation showed that the percentage of image assessed as gadobutrol was better than Gd-DTPA (41.2-44.1%) was greater than that assessed as Gd-DTPA was better than gadobutrol (5.9-26.5%). Objective evaluation showed that at 3, 7, and 10 minutes the SNR (214.17 +/- 85.70 vs. 199.57 +/- 85.08, 214.80 +/- 86.03 vs. 199.19 +/- 84.74, and 213.83 +/- 82.46 vs. 193.68 +/- 79.59, respectively), CNR (68.64 +/- 50.18 vs. 57.88 +/- 51.06, 75.42 +/- 53.19 vs. 63.74 +/- 53.91, and 77.13 +/- 51.86 vs. 63.21 +/- 51.71, respectively), CE (101.76 +/- 63.31 vs. 87.61 +/- 64.85, 99.85 +/- 61.56 vs. 85.08 +/- 64.98, and 100.33 +/- 58.63 vs. 82.73 +/- 61.73, respectively), CBR (0.48 +/- 0.32 vs. 0.40 +/- 0.33, 0.54 +/- 0.34 vs. 0.46 +/- 0.35, and 0.56 +/- 0.34 vs. 0.47 +/- 0.34, respectively), and CER (0.99 +/- 0.69 vs. 0.88 +/- 0.81, 0.97 +/- 0.68 vs. 0.86 +/- 0.84, and 0.98 +/- 0.65 vs. 0.85 +/- 0.80, respectively) were all higher when using gadobutrol compared with Gd-DTPA in the enhanced MR (repeated measures ANOVA, all P < 0.0001). On Gd-DTPA enhanced images, 289, 292, and 292 lesions at 3, 7, and 10 minutes were detected by the two radiologists, while 295, 301, and 301 lesions were detected on gadobutrol-enhanced images, respectively. ConclusionUsing a 3T T-1 FLAIR sequence, gadobutrol (0.1 mmol/kg body weight)-enhanced MR resulted in more conspicuous brain metastases, and more metastases compared with the same dose of Gd-DTPA. A delay time of 7 minutes for postcontrast MRI in patients with brain metastases is suggested in clinical practice.

Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients

Comprehensive Analysis of the Spatial Distribution of Gadolinium, Iron, Manganese, and Phosphorus in the Brain of Healthy Rats After High-Dose Administrations of Gadodiamide and Gadobutrol

Up to 52 administrations of macrocyclic ionic MR contrast agent are not associated with intracranial gadolinium deposition: Multifactorial analysis in 385 patients

Correlation between high signal intensity in cerebrum nucleus on unenhanced T1-weighted MR images and number of previous gadolinium-based contrast agent administration

Deposition of Gadolinium in the Central and Peripheral Nervous Systems and Its Effects on Sensory, Cognitive, and Athletic Implications after Multiple Injections of Gadolinium-Based Contrast Agents in Rats

Quantitative assessment of gadolinium deposition in dentate nuclei with MR fingerprinting

Gadolinium retention in the ischemic cerebrum: Implications for pain, neuron loss, and neurological deficits

Repeat and single dose administration of gadodiamide to rats to investigate concentration and location of gadolinium and the cell ultrastructure

Efficacy And Safety Of Gadobutrol (1.0 M) Versus Gadopentetate Dimeglumine (0.5 M) For Enhanced Mri Of Cns Lesions: A Phase Iii, Multicenter, Single-Blind, Randomized Study In Chinese Patients

Relationship Between High Signal Intensity in the Dentate Nucleus on Unenhanced Tt-weighted MR Images and Gadolinium Contrast Agent Administration

Ischemic Stroke Increased Gadolinium Deposition in the Brain and Aggravated Astrocyte Injury after Gadolinium‐Based Contrast Agent Administration: Linear Versus Macrocyclic Agents

The effect of macrocyclic ionic and non-ionic gadolinium agents on neuronal injury and myelin loss in the spinal cords of rats with and without diabetes mellitus

Gadolinium retention in a rat model of subtotal renal failure: are there differences among macrocyclic GBCAs?

Comprehensive phenotyping revealed transient startle response reduction and histopathological gadolinium localization to perineuronal nets after gadodiamide administration in rats

[The Characteristics of Enhanced Gadolinium DTPA Brain Magnetic Resonance Images in 298 Multiple Sclerosis Patients].

Effects of Gadolinium Retention in the Brains of Type 2 Diabetic Rats after Repeated Administration of Gadolinium‐Based MRI Contrast Agents on Neurobiology and NLRP3 Inflammasome Activation

Multicenter, intra-individual comparison of single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine for MR angiography of the peripheral arteries (the Peripheral VALUE Study).

Diagnostic value of gadobutrol versus gadopentetate dimeglumine in enhanced MRI of brain metastases.

A multicenter, randomized, controlled, single-blind comparison phase III study to determine the efficacy and safety of gadobutrol 1.0 M versus gadopentetate dimeglumine following single injection in patients referred for contrast-enhanced MRI of the body regions or extremities.

MRI Gadolinium‐Based Contrast Media: Meeting Radiological, Clinical, and Environmental Needs

Effects of gadolinium and gadolinium chelates on intracellular calcium signaling in sensory neurons